
Samsara Biocapital, LLC
About Samsara Biocapital, LLC’s 13F portfolio
Samsara Biocapital, LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Samsara Biocapital, LLC reported $1.2B across 24 US-listed positions (). Its largest position is SCHOLAR ROCK HLDG CORP (SRRK) at 31% of the reported book, and its ten biggest holdings make up 90% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: SRRK SCHOLAR ROCK HLDG CORP | $50.37 +4.94% | 31% | 6.9M | $379.4M |
| 2 | NASDAQ: ALMS ALUMIS INC | $4.33 −1.48% | 15% | 6.3M | $178.6M |
| 3 | NASDAQ: MLYS MINERALYS THERAPEUTICS INC | $14.16 +2.76% | 13% | 5.9M | $158.4M |
| 4 | NASDAQ: SEPN SEPTERNA INC | $39.20 −0.63% | 8.7% | 3.1M | $105.5M |
| 5 | NASDAQ: ALMR ALAMAR BIOSCIENCES INC | — — | 5.5% | 2.5M | $67.2M |
| 6 | NASDAQ: NGNE NEUROGENE INC | $22.93 −0.91% | 4.4% | 1.7M | $54.0M |
| 7 | NASDAQ: KLRS KALARIS THERAPEUTICS INC | $1.35 −1.46% | 4.3% | 12.9M | $52.4M |
| 8 | NASDAQ: SGP SPYGLASS PHARMA INC | — — | 3.9% | 2.1M | $47.0M |
| 9 | NASDAQ: STRO SUTRO BIOPHARMA INC | $8.72 +2.59% | 2.9% | 1.1M | $35.3M |
| 10 | NASDAQ: IVA INVENTIVA SA | $3.45 +1.77% | 2.0% | 6.3M | $23.9M |
| 11 | NASDAQ: JBIO JADE BIOSCIENCES INC | $15.06 −2.78% | 1.3% | 736K | $16.4M |
| 12 | NASDAQ: PBLS PARABILIS MEDICINES INC | — — | 1.3% | 556K | $15.2M |
| 13 | NASDAQ: VTVT VTV THERAPEUTICS INC | $16.36 +0.80% | 0.9% | 298K | $11.2M |
| 14 | NASDAQ: AQST AQUESTIVE THERAPEUTICS INC | $3.71 −1.98% | 0.9% | 2.5M | $10.4M |
| 15 | NASDAQ: NKTX NKARTA INC | $1.12 −2.61% | 0.8% | 3.5M | $9.9M |
| 16 | NASDAQ: ARTV ARTIVA BIOTHERAPEUTICS INC | $3.83 +1.59% | 0.8% | 955K | $9.3M |
| 17 | NASDAQ: RANI RANI THERAPEUTICS HLDGS INC | $0.58 −10.42% | 0.6% | 10.4M | $7.9M |
| 18 | NASDAQ: AGMB AGOMAB THERAPEUTICS NV | — — | 0.6% | 600K | $7.8M |
| 19 | NASDAQ: ABVX ABIVAX SA | $80.65 −3.79% | 0.6% | 55K | $7.3M |
| 20 | NASDAQ: XFOR X4 PHARMACEUTICALS INC | $2.96 −0.67% | 0.5% | 1.4M | $6.5M |
| 21 | OTC: ELOX ELOXX PHARMACEUTICALS INC | $10.65 +2.31% | 0.5% | 400K | $5.6M |
| 22 | NASDAQ: CHRS COHERUS ONCOLOGY INC | $0.39 −5.56% | 0.4% | 3.4M | $4.8M |
| 23 | NASDAQ: UPB UPSTREAM BIO INC | $2.00 −3.85% | 0.2% | 354K | $2.4M |
| 24 | NASDAQ: GOSS GOSSAMER BIO INC | $11.23 −1.75% | 0.1% | 7.2M | $1.2M |
Showing the 24 largest positions reported in this 13F.
- Healthcare88%
- NewALMRALAMAR BIOSCIENCES INC—$67.2M
- AddedIVAINVENTIVA SA+21.6%$23.9M
- NewPBLSPARABILIS MEDICINES INC—$15.2M
- NewARTVARTIVA BIOTHERAPEUTICS INC—$9.3M
- AddedRANIRANI THERAPEUTICS HLDGS INC+22.0%$7.9M
- NewELOXELOXX PHARMACEUTICALS INC—$5.6M
- ReducedKLRSKALARIS THERAPEUTICS INC−0.5%$52.4M
- ReducedJBIOJADE BIOSCIENCES INC−24.0%$16.4M
- ReducedABVXABIVAX SA−2.6%$7.3M
- ReducedXFORX4 PHARMACEUTICALS INC−23.8%$6.5M
- ReducedUPBUPSTREAM BIO INC−51.9%$2.4M
- SoldPVLAPALVELLA THERAPEUTICS INC NE−100%—
- SoldACLXARCELLX INC−100%—
Reading Samsara Biocapital, LLC’s 13F portfolio
Samsara Biocapital, LLC’s $1.2B 13F book is spread across 24 reported positions and is highly concentrated — its ten largest positions alone are 90% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are SRRK, ALMS, MLYS, SEPN and ALMR, led by SCHOLAR ROCK HLDG CORP (SRRK) at 31% of the portfolio. The heaviest sector exposure is Healthcare (88%).
What Samsara Biocapital, LLC changed last quarter
Between 2026-03-31 and Q2 2026, Samsara Biocapital, LLC was a net seller: it opened 4 new positions and added to 2 more, while trimming 5 and closing 2 outright. Against a 24-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was ALAMAR BIOSCIENCES INC (ALMR), and its biggest reduction was KALARIS THERAPEUTICS INC (KLRS).
What a 13F does and doesn’t reveal
A 13F captures only Samsara Biocapital, LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Samsara Biocapital, LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Samsara Biocapital, LLC's profile on this page is built directly from those filings.
How current is the 13F data on Samsara Biocapital, LLC's page?
It reflects Samsara Biocapital, LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Samsara Biocapital, LLC files its next quarterly report, this page refreshes automatically.
Can I see Samsara Biocapital, LLC's complete list of holdings?
This page highlights Samsara Biocapital, LLC's largest positions rather than all 24 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Samsara Biocapital, LLC's filings.
Does a 13F show everything Samsara Biocapital, LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Samsara Biocapital, LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Samsara Biocapital, LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

